Ruboxistaurin Mesilate Hydrate

N/A

Report date: 2024/02/22 15:13:57
NME

Base Information

Drug NameRuboxistaurin Mesilate Hydrate
Drug Alias Nameruboxistaurinum卢博滔林芦布妥林ruboxistaurinaArxxant +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein kinase C beta inhibitorsGlycogen synthase kinase-3 beta inhibitors
TargetsProtein kinase C betaGlycogen synthase kinase-3 beta
Therapy Area/IndicationsDiabetic macular oedemaDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1 +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[27] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesDermbiont Inc
Inactive CompaniesThe Brigham and Women's HospitalRecursion Pharmaceuticals IncChromaderm Inc +[6] 
Active IndicationsMelanosisHyperpigmentation
Inactive IndicationsDiabetic macular oedemaDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1 +[9] 

Other Information

ATC CodeN/A
Related LinksWikipedia